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Background: The tumor microenvironment (TME) is critical to every aspect of cancer biology.
Organotypic tumor slice cultures (TSCs) preserve the original TME and have demonstrated utility in
predicting drug sensitivity, but the association between clinicopathologic parameters and in vitro TSC
behavior has not been well-defined.
Methods: One hundred and eight fresh tumor specimens from liver resections at a tertiary academic center
were procured and precisely cut with a Vibratome to create 250 μm × 6 mm slices. These fixed-dimension
TSCs were grown on polytetrafluoroethylene inserts, and their metabolic activities were determined by a
colorimetric assay. Correlation between baseline activities and clinicopathologic parameters was assessed.
Tissue CEA mRNA expression was determined by RNAseq.
Results: By standardizing the dimensions of a slice, we found that adjacent tumor slices have equivalent
metabolic activities, while those derived from different tumors exhibit >30-fold range in baseline MTS
absorbances, which correlated significantly with the percentage of tumor necrosis based on histologic
assessment. Extending this to individual cancers, we were able to detect intra-tumoral heterogeneity over a
span of a few millimeters, which reflects differences in tumor cell density and Ki-67 positivity. For colorectal
cancers, tissue CEA expression based on RNAseq of tumor slices was found to correlate with clinical
response to chemotherapies.
Conclusions: We report a standardized method to assess and compare human cancer growth ex vivo
across a wide spectrum of tumor samples. TSC reflects the state of tumor behavior and heterogeneity, thus
providing a simple approach to study of human cancers with an intact TME.
Keywords: Organotypic; microenvironment; heterogeneity; cancer model
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Introduction
In the current era of molecular oncology, patient-derived
models that can accurately inform clinical decisions are
urgently needed. Cancer is a diverse collection of diseases
with enormous biologic and genomic heterogeneity, thus
precision medicine, i.e., matching the right drugs with the
right patients, has been an ongoing challenge. Advances in
the molecular profiling of tumors through next-generation
sequencing have led to new treatment paradigms with
astonishing results for select patients, but it is estimated that
fewer than 5% of patients with advanced cancers currently
benefit from this approach (1). Many reasons contribute
to this lackluster result, including a shortage of functional
assays, the absence of effective therapies targeting common
cancer genes such as RAS and p53, and the emergence
of resistance stemming from functional compensation by
other genes (2-4). Further, a single mutation may play
different roles in different tumors, as highlighted by the
variable response of BRAF (V600E)-associated nonmelanoma cancers to the BRAF inhibitor vemurafenib (5).
At present, therapeutic decisions are based on a limited set
of ‘actionable’ genomic data, without a full understanding
of its biologic significance. Thus, a lack of individualized
functional assays is a major shortcoming in the current
practice of precision oncology.
Human cancer models have become more prevalent with
the increasing availability of organoid technology and in vivo
patient-derived xenograft (PDX) mouse models (6,7). While
these methods have yielded valuable biologic insights, one
shared pitfall of these techniques is the inability to maintain
the original tumor microenvironment (TME). Organotypic
tissue slice cultures (TSCs) have been used for decades to study
the physiologic properties of intact tissues, such as those of
the central nervous system (8). Recent studies using TSCs as
an ex-vivo model to predict drug sensitivity in cancer therapy
have led to renewed interest in this platform, with investigators
demonstrating preservation of the TME, molecular signaling,
and treatment responses (9-12). Recently, we reported that
slices from human pancreatic cancers remain viable in vitro
and retain their TME, including the local immune milieu,
thus allowing investigations of tumor immunology (13).
Widespread application of TSCs in personalized oncology
has lagged due to the absence of standardized methods for
comparison between samples. Furthermore, there has been a
paucity of evidence demonstrating that organotypic cultures
reflect clinical characteristics of human cancers. Here we
report a simple protocol that can be applied to diverse solid
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human gastrointestinal malignancies, and demonstrate the
biologic relevance of TSCs by comparing in vitro growth
properties with clinical and pathologic parameters. Using
standardized readouts, this system allows us to compare and
characterize inter- and intra-tumoral heterogeneity that
correlates with the biologic state of the disease.
Methods
Subjects and clinical data
Patients undergoing liver resection for primary or
metastatic tumors were consented for tissue donation under
IRB-approved protocols (University of Washington IRB
#1852 and #1666). Fresh biospecimens were collected from
a total of 108 patients over a two-year period, along with
relevant de-identified clinical data.
Sample preparation
Sterile specimens from hepatectomies were processed
immediately at the completion of resection under
the direction of the surgeons (JO Park, RS Yeung) in
consultation with Pathology staff (M Yeh). To maintain
maximal sterility of the specimens, the latter were placed
in a sterile field within the operating room. Following the
directives of the pathology representative, ‘to-be-discarded’
tissues were procured in a sterile environment, usually
within 10 minutes of the resection.
Tissue procurement
In order to establish a reproducible protocol that allows for
comparison between samples, we aimed to generate tissue
slices of a fixed volume. Six-mm tissue cores were procured
from specimens using a sterile biopsy punch (Integra
Miltex, York, PA), and immediately placed in cold BelzerUW solution (Bridge to Life Ltd., Columbia, SC) prior
to transfer to research laboratories. We found that 6-mm
cores are optimal for tumors >2 cm without interfering with
clinical diagnosis. In our hands, smaller cores down to 4-mm
worked equally well although the signals from the MTS
assay were proportionally reduced.
Precision-cut slices
Please refer to Supplemental Methods for step-by-step
protocol. Briefly, 250 µm thick tumor slices were cut using
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a Leica VT 1200S vibrating microtome (Leica Biosystems
Nussloch GmbH, Germany) with the following settings:
amplitude 2–3 mm and speed 0.5–1.5 mm/s, depending
on tissue consistency. Tissue slices were washed with
Williams’ Media E (Gibco, Grand Island, NY, USA), placed
on Millicell Cell Culture Inserts (0.4 µm PTFE, EMD
Millipore, Burlington, MA) in 24-well cell culture plates
containing growth media, and incubated at 37 ℃ in 5%
CO2 on a lab rocker set at 20 rotations/min.
Culture conditions
Tumor slices were cultured in Williams’ Media E containing
nicotinamide (12 mmol/L), L-ascorbic acid 2-phosphate
(50 mg/mL), D-(+)-and Glucose (5 mg/mL) (Sigma-Aldrich,
St. Louis, MO, USA); Sodium Bicarbonate (2.5%), HEPES
(20 mmol/L), Sodium Pyruvate (1 mmol/L), Glutamax (1%),
and Penicillin Streptomycin (0.4%) (Gibco, Grand Island,
NY, USA); ITS + Premix (1%), Human EGF (20 ng/mL)
(BD Biosciences, San Jose, CA, USA). Media were changed
one day after slicing and then every 2–3 days.
MTS assay
Cell viability was assessed using the CellTiter 96® AQueous One
Solution Cell Proliferation Assay (3-(4,5-dimethylthiazol2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium; MTS) (Promega, Fitchburg, WI, USA). Slices
were incubated with MTS reagent while rocking at 37 ℃
for 2 or 3 hours. Media were transferred to a 96 well plate;
absorbance was read at 490 nm and normalized to blanks
(wells containing media and MTS without tissue slices). After
MTS measurements, slices were either fixed in 10% formalin
for 24 hours at 4 ℃ or placed back in their original cell
inserts for continued culturing.
Histology and immunohistochemistry
Fixed slices were embedded in paraffin, and 4µm thick
sections were cut and placed on glass slides. Slides were
stained with hematoxylin and eosin or processed for Ki67 immunohistochemistry (IHC) as described (14). To
determine the Ki-67 positive fraction, the number of
stained cells in at least 10 high power fields was counted.
Tumor cell transcriptomics
Tumor slices were dissociated using the gentleMACS system
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(Miltenyi Biotec) and loaded on a Chromium instrument (10X
Genomics) for single-cell RNA processing and 150 cycles
of NextSeq500 (Illumina) sequencing. Reads were aligned
to the human genome (GRCh38) and quantified using
CellRanger v2 software. Tumor and non-tumor cells were
computationally segregated by K-means clustering. Average
CEACAM5, KRT20, and GAPDH expression levels were
calculated for the EPCAM-expressing tumor cell clusters.
Statistical analyses
R statistical software was used to develop a predictive model
for high MTS values based on univariate and multivariate
linear regression. Clinical covariates included age, sex, body
mass index (BMI), history of smoking, any prior cancer
treatments (surgical resection, radiofrequency ablation
(RFA), chemotherapy, etc.), number of prior chemotherapy
regimens, maximum liver tumor and primary tumor size of
non-liver tumors, known metastatic disease, and number of
tumors. Pathologic covariates included histology, maximum
focus size and percent of viable/necrotic tissue in resected
specimens, tumor regression grade (TRG) score, tissue
fibrosis, tissue differentiation, maximum mitotic activity
per high power field, and presence of nodal disease. Data
were analyzed as continuous or discrete numeric variables,
or as categorical or binary variables. Results for univariate
and multivariate analyses are reported as slope coefficients
for covariates of interest with 95% confidence intervals
calculated from robust standard errors, P values for
coefficients, and R2 values for each model. For the leave one
out cross validation (LOOCV) analysis, results presented
for comparison are the covariates included in each model,
root-mean-squared errors (RMSE), and R 2 values to
compare predictive accuracy of the models.
Results
Standardized assessment of human cancer tissue slice
cultures
We set out to standardize our TSC platform, which allowed
us to compare results between different tumor samples. As
a quantitative readout, we used a colorimetric MTS assay
to measure metabolic activity as our primary endpoint (15).
This assay has the key advantage of low toxicity of MTS
reagent, enabling multiple assessments of the same sample
over time. In our experience, MTS absorbance remains
stable over at least 3 repeated assays on any one sample
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Figure 1 Standardized assessment of tumor slice cultures (TSCs) by precision cutting. (A) Workflow of the TSC platform from surgical
specimen to slices. Left, representative tumor ‘wedge’ removed from surgical specimen; middle, 6-mm core from a punch biopsy; right,
agarose-embedded cores set in Vibratome for slicing. Refer to Supplemental Methods for details; (B) comparison of baseline MTS
absorbance with and without normalization to wet weight of slices from 2 cases of metastatic colorectal carcinoma (CRC). The table shows
the variance of weight and absorbance measurements; (C) baseline MTS absorbance of 3 consecutive TSCs each from 4 different tumors
without normalization to wet weight. HCC, hepatocellular carcinoma.

(data not shown). Next, we considered a number of
methods to standardize MTS absorbance across different
samples, including normalizing data to the wet weight of
the slices, tissue volume, or total protein content. The
latter method requires destruction of the sample, which
would eliminate our ability to perform longitudinal studies
such as drug sensitivity testing. Instead, we standardized
the volume of tissue in our cultures using a precision-
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cutting vibratome (Leica) to generate 250 µm thick slices
from 6-mm cores, resulting in thin cylinders with a fixed
volume of approximately 7 mm3 (Figure 1A). Baseline MTS
measurements from consecutive slices from the same core
were determined with and without normalization to the
wet weights of individual slices. Figure 1B shows the results
from two colorectal carcinoma (CRC) TSCs, highlighting
significant variability in the wet weights of the slices, while
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baseline MTS absorbances were highly homogeneous.
In our hands, we found greater variability when the
colorimetric absorbance was normalized to the wet weights
of each slice. We attribute these results to our inability to
precisely control the fluid or water content of slices during
the weighing process while maintaining tissue viability,
and postulate that this water content does not affect MTS
values. Therefore, standardizing the slice dimensions without
normalization had significantly less variance (Figure 1B table).
We further confirmed that consecutive precision-cut slices
from the same core of tumors of various histologies have
nearly identical baseline MTS absorbance, obviating the need
for additional normalization (Figure 1C). The simple step of
standardizing the dimensions of the tumor slices allowed us
to obtain highly reproducible assessment of the global ‘health’
of individual slices at baseline, thus enabling us to compare
results among samples.
Culture viability and integrity
Next, we examined the viability of TSCs over time. In
the majority of cases, MTS measurements did not change
over the first week in culture, as illustrated by the four
independent tumors shown in Figure 2A. In further support
of in vitro maintenance of growth, corresponding Ki-67+
fractions in each of these TSCs remained stable over the
7-day period (Figure 2B). Figure 2C shows tumor histology
and Ki-67 IHC in CRC, hepatocellular carcinoma (HCC),
and intrahepatic cholangiocarcinoma (ICC) TSCs on days
0 and 7, demonstrating that tumor architecture is preserved
over time in TSCs, as are their proliferative activities.
In our experience with 108 consecutive tumors, we were
able to generate TSCs in 89% of cases, thus making this
technique highly reliable and efficient in creating patientspecific cancer models for short-term investigation. Of the
different tumor histologies from which we have generated
TSCs, CRCs best maintain their ‘health’ in vitro, with a
survival rate of 98%, while HCCs and ICCs show greater
decline in their viability over the course of a week (65%
and 71% survival, respectively). In an attempt to optimize
conditions for HCC slices, we varied levels of serum,
glucose, growth factors, and matrix in our cultures, but
did not observe a consistent improvement in TSC survival
over a two-week period with any of these changes (data not
shown). As a result, we used uniform media and growth
conditions for all tumor samples going forward (i.e., after
our first 30 cases). Our current protocol is detailed in the
Supplemental File.

© Annals of Translational Medicine. All rights reserved.
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Correlation of TSC viability with clinical and pathologic
parameters
We t a b u l a t e d b a s e l i n e M T S a b s o r b a n c e s f r o m
53 consecutive samples representing diverse tumor types
following the standardization of our protocol; the clinical
characteristics of the study cohort are summarized in Table S1.
Figure 3 shows the mean baseline MTS absorbance from a
minimum of three TSCs derived from 51 of these 53 cases;
two cases in this initial cohort failed to cut due to poor tumor
consistency. One can readily appreciate the wide range of
baseline MTS values (i.e., 0.076 to 3.396), indicating the
tremendous variability in growth and proliferative activity
among different tumors at the time of resection.
We postulated that baseline MTS values reflect the
variable biologic activities of the in vivo state, and may
correlate with clinical and pathologic features. Univariate
analyses based on the clinical and pathologic parameters
shown in Table 1 identified three factors that correlated with
in vitro viability scores (MTS values): (I) maximum tumor
size on preoperative imaging (slope coefficient b =−0.083,
P=0.02); (II) “other” histologic cancer type (b =−0.70,
P=0.02); and 3) percent tumor necrosis on histologic
examination (b =−0.012, P=0.005). Baseline MTS activities
did not meaningfully differ between CRC, HCC, or ICC,
nor did it correlate with age, sex, history of smoking, prior
cancer treatment, number of neoadjuvant chemotherapy
regimens, tumor regression grade, tissue fibrosis, tissue
differentiation, mitotic activity, or nodal disease. Primary
tumor size on preoperative imaging (b =−0.078, P=0.06),
metastatic disease (b =−0.56, P=0.10), maximum viable
focus size (b =−0.064, P=0.07), and percent tumor viability
(b =0.006, P=0.10) trended toward associations with
in vitro viability, but did not reach statistical significance on
univariate analysis.
A multivariate linear regression model chosen a priori,
controlling for histologic cancer type, metastatic disease,
maximum tumor size, maximum focus size, and percent
necrosis, found that lower mean percent necrosis remained
associated with higher baseline mean MTS (b =−0.012, 95%
CI: −0.0211, −0.00273, P=0.01). Other covariates in the
multivariate model did not show a significant association
with mean MTS, though histologic cancer type of “other”
still showed a trend of lower mean MTS compared to CRC
as a reference (b =−0.471, P=0.08).
Comparing this model with several others for internal
validity, we found a consistent association between mean
percent necrosis and mean baseline MTS regardless of
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staining and Ki-67 immunostaining corresponding to samples highlighted in A. CRC, colorectal carcinoma; HCC, hepatocellular carcinoma;
ICC, intrahepatic cholangiocarcinoma. Original magnification 200×.

the number of other covariates included in the model.
Using LOOCV with complete cases as described in
methods, we determined that a model including metastatic
disease, maximum tumor size, maximum viable focus
size, and percent necrosis (Table 2) had the best predictive
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accuracy for in vitro viability, given it is lowest comparative
RMSE and highest comparative R2 (Model #4 in
Table S2). Together, these findings indicate that baseline
MTS absorbance in TSCs mirrors tumor viability at the
time of resection across all tumor types.
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cholangiocarcinoma; FNH, focal nodular hyperplasia; FLC, fibrolamellar carcinoma.

Assessment of tumor heterogeneity
While there is clear evidence that genomic and
transcriptomic heterogeneity exist within different parts of a
given tumor, less is known about intra-tumoral variability in
terms of metabolic activity. Our ability to detect metabolic
differences among tumors (see Figure 3) suggested that our
TSC method could also identify metabolic heterogeneity
within tumors. We examined heterogeneity within tumors at
two levels: regional differences that span several centimeters
within a larger tumor, and local heterogeneity within a few
millimeters. Figure 4A shows examples of baseline MTS
values from separate tumor cores separated by at least
1 cm obtained from tumors that were >3 cm in diameter,
i.e., regional differences within tumors. Given that the
central portion of a large solid tumor is often necrotic,
we purposely took samples from the periphery of tumors,
where tissue is expected to be more viable. Nonetheless,

© Annals of Translational Medicine. All rights reserved.

we observed significant differences in baseline MTS
values from separate sites within each tumor in 4 out of
5 cases (Figure 4A). We found that the variation in baseline
metabolic activity correlates with the distribution of tumor
vs. stromal components represented by each slice. Figure 4B
illustrates the histology of the 3 sites from CRC-1 shown
in Figure 4A. Of the 3 areas, Site 2 has extensive collagen
deposition with only small areas of necrotic tumor cells,
whereas Sites 1 and 3 contain significantly more viable
tumor cells. Correspondingly, Site 2 had the lowest baseline
MTS absorbance. On closer inspection, tumor cells occupy
a significantly larger area of Site 1 compared to Site
3 despite similar MTS absorbance. We thus hypothesized
that tumor cells in site 3 were more mitotically and/or
metabolically active than at the other two sites. Ki-67 IHC
demonstrated a significantly higher fraction of Ki-67+ tumor
cells in site 3 compared to site 1 (82% vs. 21%; Figure 4B).
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Table 1 Univariate linear regression of average baseline MTS value with clinical and pathologic parameters
Clinical parameter

Slope coefficient

95% confidence intervala

P value

R2

Age

0.0121

−0.00551 to 0.0299

0.173

0.0339

Male

−0.0105

−0.4863 to 0.465

0.965

3.88e-5

BMI

0.0281

−0.0188 to 0.0749

0.235

0.0324

History of Smoking

0.0163

−0.457 to 0.457

0.945

7.58e-5

Prior treatment

0.215

-0.231 to 0.662

0.338

0.0157

Prior chemotherapy regimens

0.0027

0 (reference)
1

0.0895

−0.448 to 0.628

0.740

≥2

0.0246

−0.624 to 0.673

0.940

Maximum tumor size

−0.0828*

−0.15 to −0.0161

0.0159

0.081

Primary tumor size

−0.0781

−0.016 to 0.00418

0.0623

0.054

Metastatic disease

−0.557

−1.22 to 0.1107

0.1002

0.0304

Number of tumors

−0.0141

−0.067 to 0.0388

0.594

0.00549

Pathologic parameter
Histologic cancer type

0.114

CRC (reference)
HCC

−0.283

ICC

0.0499

Other
Maximum Focus Size

0.413

−0.685 to 0.785

0.892

−0.698*

−1.28 to −0.119

0.0191

−0.0644

−0.134 to 0.00512

0.0685

0.0558

−0.0808 to 0.359

0.208

0.0404

−0.00131 to 0.0141

0.1013

0.0651

Tumor Regression Grade

0.139

Percent viability

0.006387

Percent necrosis

−0.973 to 0.406

−0.0121*

−0.0204 to −0.0038

0.0052

0.149

0.222

−0.277 to 0.7195

0.374

0.159

Differentiation

−0.158

−0.72 to 0.404

0.574

0.00796

MMA/hpf

−0.0169

−0.0544 to 0.0207

0.369

0.00938

Fibrosis

N Stage

0.0451

N0 (reference)
≥ N1

0.366

−0.173 to 0.905

0.179

Nx (unknown)

0.0253

−0.686 to 0.737

0.943

BMI, body mass index; CRC, colorectal cancer; HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocarcinoma; MMA/hpf,
maximum mitotic activity per high power field. a, calculated with robust standard errors; *, statistically significant.
Table 2 Best predictive multivariate linear regression model of average baseline MTS value
Model covariates
Metastatic disease

Intercept

Slope coefficient

2.26

95% confidence intervala

P value

−0.732

−1.63 to 0.168

0.108

Maximum tumor size

−0.0463

−0.131 to 0.0380

0.273

Maximum focus size

−0.0624

−0.144 to 0.0197

0.132

Percent necrosis

−0.0117

−0.0211 to −0.00220

0.0171

R2

Adjusted R2

0.318

0.247

a

calculated with robust standard errors.
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Figure 4 Baseline MTS value as an indicator of intra-tumoral heterogeneity. (A) Regional heterogeneity: MTS values from tumor cores
obtained from 3 different sites within tumors >3 cm from 5 different patients. Each site is at least 1 cm from the others and is representd
by at least 3 slices. *, P<0.05 compared to site 1; (B) histologic correlation with baseline MTS from CRC-1 shown in A. Top panels: H&E
representing each of the 3 sites; bottom panel: Ki-67 IHC of cores from site 1 and site 3. Even though site 1 is more cellular than site 3,
the proportion of Ki-67+ cells is significantly lower than site 3 (site 1: 21% vs. site 3: 82%). All photos are at 40× magnification; (C) local
heterogeneity: Each tumor core was sectioned serially along its length and baseline MTS values were determined for each slice. Left column:
Examples of tumor cores showing minor heterogeneity (<1 absorbance unit variation). Right column: Examples of tumor cores showing major
heterogeneity (>1 absorbance unit variation). Examples of tumor histology indicated by the red circles are shown in two cases of CRC. Tumor
cells are highlighted by purple stain. CRC, colorectal carcinoma; HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocarcinoma.
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0.5

for 72 hrs based on RNAseq. Figure 5 illustrates that
tissue CEACAM5 (gene encoding CEA) mRNA levels
were significant higher in tumor slices from patients who
were deemed clinically chemo-resistant. In other words,
CEACAM expression inversely correlated with clinical
response. This was not due to differences in the viability
of the slices between chemo-resistant and chemo-sensitive
tumors, given comparable expression of GAPDH and
cytokeratin 20 (KRT20) genes.

0.0

Discussion

RESPONSE

resistant

sensitive
P=0.47

Expression

1.5

1.0
P=0.02
P=0.16

CEACAM5

KRT20

GAPDH

Figure 5 Tissue mRNA expression of CEA correlates negatively
with clinical response to chemotherapies. Tumo slices from
metastatic CRC in the liver were analyzed by RNAseq to
determine level of expression of CEACAM5 gene that encodes
CEA. Results are compared to those of cytokeratin 20 (KRT20)
and a housekeeping gene, GAPDH. Response groups are based
on clinical data from patients receiving chemotherapies prior the
surgical resection.

These data suggest that both tumor cell density and their
proliferative activities influence baseline MTS values in
CRC metastases.
To examine local heterogeneity within a span of
millimeters, we analyzed consecutive tumor slices over
the length of individual tissue cores (~1 cm). Of the eight
samples analyzed in this fashion, four had similar MTS
values (i.e., minor heterogeneity is defined as variability
within 1 unit of absorbance) across the length of the
cores, while the other 4 showed significant heterogeneity
over similar distances (i.e., >1 unit of drift in absorbance;
Figure 4C). Histologic examination revealed a correlation
between MTS absorbance and the proportion of viable
cancer cells within each slice (Figure 4C, bottom). Thus,
within the CRC tumor microenvironment, tumor cells
(as opposed to stromal cells) are the major contributor of
metabolic activity in slice cultures.
Tumor CEA correlates with clinical response to
chemotherapy
Baseline serum carcinoembryonic antigen (CEA) has been
shown to be an independent poor prognostic factor in
advanced CRC (16). Here, we measured mRNA expression
of CEACAM genes from CRC tumor slices in culture

© Annals of Translational Medicine. All rights reserved.

In this study we describe a standardized method to evaluate
human-derived TSCs in vitro across a broad spectrum
of primary and metastatic liver cancers. Specifically, we
developed a simple and reproducible protocol that maintains
tumor viability for days, and allows for comparison among
fixed-volume samples generated by precision cutting with
a vibratome. While previous studies have emphasized the
utility of organotypic slice cultures to test drug sensitivity
in individual cancers, few studies have compared biologic
endpoints among different tumors. Here, we show that
baseline MTS absorbance of fixed volume slices provides a
quantitative measure of the metabolic activity that accurately
reflects disease viability and biologic status of the tumor
at the time of resection. Applying the MTS assay across
different TSC samples provides a simple way to compare
cancer metabolic activity and viability in a cohort of patients.
In our experience of over 100 cases, we have optimized
and standardized our protocol for multiple types of
primary and secondary liver tumors. We have learned that
consecutive slices of fixed dimensions have nearly identical
metabolic/growth activity, and thus serve as biologic
replicates in experiments. By the same token, we can exploit
TSCs to evaluate tumor heterogeneity in human cancers.
Tumor tissues that are separated by even a few millimeters
can exhibit significant changes in MTS values, reflecting
underlying differences in the distribution of tumor cells
within a cancer. In our tumor samples from liver metastases,
the majority of patients had received pre-operative systemic
therapy. The correlation between baseline MTS absorbance
and the amount of histologically necrotic tumor allows us
to quantitatively gauge the effectiveness of neoadjuvant
therapy at the time of resection, independent of standard
pathologic evaluation. For CRCs, we also found that tissue
CEA mRNA levels negatively correlated with clinical
response to chemotherapies.
A key advantage of using TSC as a model of human
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cancer is the ease and efficiency in generating an in vitro
system that preserves the tumor microenvironment. We
have exploited this feature in addressing the immune
landscape in human malignancies (13,17) that is not easily
reproduced in other systems including cell lines, organoids,
and PDX mice. There is no lag time associated with TSC;
slices can be put to use almost immediately upon culture
and without concerns for selection pressure. With a success
rate of nearly 90% in establishing TSC in our sample
set, the model provides a simple method to study human
cancers while preserving the original spatial architecture
and elements of the TME.
There are a few important limitations in using the TSC
platform. First and foremost is that the lifespan of tumor
slices is finite and non-renewable, thus long-term or repeat
experiments are limited. Efforts are currently underway to
optimize cryopreservation methods such that the slices can
be studied at any time. Not all tumors behave the same;
in our experience, metastatic colorectal metastases are the
most hardy to grow in vitro unless they have undergone
extensive necrosis from prior chemotherapy. On the other
hand, tumors such as hepatocellular carcinoma are more
variable in their ability to remain viable long-term in
culture. For any particular sample, there remains many
conditions that can be fine-tuned for optimal growth
including, but not limited to, components of the media,
thickness of the slice, ambient oxygen level, and the extent
of physical motion. Our protocol provides a starting point
for anyone who wants to explore this method in their
studies. Access to fresh, sterile tumor specimens is critical
to creating TSCs, and at our Institution, this effort is led
by surgeons who, in collaboration with pathologists, have
developed a highly efficient practice of procuring samples
without compromising clinical care. In the future, we
anticipate modification of our technique to adopt coreneedle biopsies, which will expand the clinical applications
greatly in the field of precision oncology by bridging ‘omics’
data with functional biologic assays.
In summary, our study highlights a simple, standardized
method to generate TSCs from solid tumors using a fixed
volume of tissue, which allows for sample comparison. Besides
the ability to test drug sensitivity, properties inherent in the
tumor slices provide biologic information that are clinically
relevant. We show that TSCs provide a functional platform
that is useful in detecting inter- and intra-tumor heterogeneity,
a feature that needs to be taken into consideration in order to
optimize treatment recommendations and improve outcome
for individual cancers.
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Supplementary

Supplemental methods
Reagents
Belzer UW Cold Storage Solution (Bridge to Life)
5 mL Eppendorf tubes (cat. no. 0030119487)
48-well cell culture plates (Corning, C3548)
24-well cell culture plates (Corning, C3527)
96-well assay plate—Corning Costar Assay Plate, clear, flat bottom, 9017
Millipore Cell Culture Inserts (PTFE 0.4µM pore) PICM01250 Millipore Sigma
#10 Scalpels (Exel International, 29550)
Sterile gauze (Covidien, Curity 3157)
Sterile petri dish (Fisher Scientific, FB0875713)
CellTiter 96 Aqueous One Solution Cell Proliferation Assay (MTS), (Promega,G3580)
UltraPure Low Melting Point Agarose (cat. no. 16520100)
DPBS (Gibco – 14190144)
Williams medium E (Gibco-Invitrogen cat# 12551-032)
L-Glutamine (Gibco-Invitrogen cat#25030-081)
Nicotinamide (Sigma N-0636)
Asorbic acid (Sigma cat# A8960)
Sodium Bicarbonate (Gibco-Invitrogen cat#15630-080)
D-Glucose (Sigma cat# G5767-500G)
Sodium Pyruvate (Gibco-Invitrogen cat#11360-070)
HEPES (Gibco-Invitrogen cat#15630080)
ITS + Premix (BD Biosciences cat#354352)
Penicillin-Streptomycin (Gibco-Invitrogen cat# 15140-122)
Human EGF (BD Biosciences cat# 354052)
Microsette Six Compartment Biopsy Cassettes (Fisher, 15182705C)
Tools
Lieca VT 1200S Vibrating Microtome (Leica Biosystems, Germany)
Blades (double edge, PTFE coated) (Ted Pella, 121-6)
Adhesive (Ted Pella, 7085-85-0)
Debonder (Ted Pella, 75-52-5)
Rocker Model 55 Variable Speed (Reliable Scientific)
Sterile forceps
Sterile Curved Spatula
Microplate Reader (Molecular Devices, Optimax)
6-mm Disposable Biopsy Punch (Integra-Miltex 33-36)
Preparation of 2% agarose solution
Add 1 gram of low melting point agarose to 25 mL of sterile dPBS in a sterile 250 ml Erlenmeyer flask. Microwave on low
power until agarose has completely dissolved. Stop microwave and swirl liquid every 20 seconds so contents do not boil over.
Let cool down slightly in 37-degree water bath and then add 25 mL of Williams Medium E. Leave in 37-degree water bath
until ready to use.

Preparation of modified WME
Williams’ Media E containing:
nicotinamide (12 mmol/L)
L-ascorbic acid 2-phosphate (50 mg/mL)
D-(+)-and Glucose (5 mg/mL)
Sodium Bicarbonate (2.5%)
HEPES (20 mmol/L)
Sodium Pyruvate (1 mmol/L)
ITS premix (1%)
Glutamax (1%) or L-glutamine (1%)
Penicillin Streptomycin (0.4%)
Human EGF (20 ng/mL)
Procedure
Preparation for slice experiment
(I)
(II)
(III)
(IV)
(V)

Prepare 5 mL Eppendorf collection tube with 3 mL of Belzer UW Cold Storage Solution. Keep on ice.
Prepare wash buffer, WME media with 1% Penicillin Streptomycin.
Prepare modified WME.
Transfer 400 µL of WME with 1% Penicillin Streptomycin into each well of a 48 well plates, depending on the
number of slices desired, and place in tissue culture incubator.
Prepare 2% agarose solution and place in 37-degree water bath.

Collection of human tissue
(I)

Criteria for research collection.
i. Resection of primary or secondary liver tumors
ii. Tumor is greater than 2 cm in diameter
iii. Margins and pathologic assessment will not be compromised from the tissue collection.
(II)
The specimen is placed on the sterile field immediately upon completion of the resection. In the presence of
a pathology representative, a wedge of tumor tissue of ~1 cm thick is removed from the specimen using sterile
instruments. This is done without sacrificing or violating any potential tissue or margins that are needed for clinical
evaluation.
(III) The tumor tissue wedge is cored using the 6-mm biopsy punch. Using non-tooth pick-ups, cores are placed directly in
3 mL of ice-cold Belzer UW Cold Storage Solution in 5 mL Eppendorf tubes and placed on ice. To maximize tissue
viability, cores are taken from the periphery of the tumor to avoid areas of central necrosis.
(IV) Tissue is transported on ice immediately to the lab for processing. These steps are usually completed within
10 minutes of surgical resection.
Preparation of tissue
(I)
(II)
(III)
(IV)
i.
(V)

Place buffer tray in holder and cover. Add ice around buffer tray.
Tissue cores are removed from UW solution with sterile forceps and placed in a sterile petri dish.
Excess liquid is dabbed off on sterile gauze.
Tissue cores can be directly glued to the specimen disc with adhesive for slicing.
Longer cores can be cut in half with sterile scalpel.
Or cores can be embedded in 2% agarose solution for slicing.

i.
(V)
(VI)

Embedding in agarose is important for softer tissue cores.
Position core in the center of one well of a sterile 24 well plate.
Pipet 37 ℃, 2% agarose solution over top of core(s) in each well until tissue is entirely covered, place cover on plate,
and place on ice.
(VII) Agarose will solidify in less than 5 min.
(VIII) Once the agarose has solidified use a sterile scalpel or spatula to cut along the edge of the agarose in the well. With a
scooping motion pop the embedded tissue course out of the well and onto a petri dish.
(IX) Using a drop of superglue, glue the face of the embedded core that was on the bottom of the well directly to the
specimen disc. Ensure that both the tissue and agarose are in contact with the adhesive. The top of the agarose will
have a concave shape.
(X)
Up to 4 cores in agarose or 6 not it agarose can be glued to the specimen disc at one time for efficient slicing.
(XI) The specimen disc is then placed in the buffer tray and the buffer tray is filled with ice cold Belzer UW solution.
Preparation of tumor slices
(I)
(II)
(III)
(IV)
(V)

Place the ice tray onto the vibratome and secure.
Rotate blade to position 2.
Raise the stage up using the control pad until the blade touches the liquid in the buffer tray.
Set cutting window using the control pad.
Once the window is set, using the run feature step down 250 microns at a time at a 1.5 mm/s until the blade reaches
the tallest tissue core.
(VI) Adjust settings on the vibratome depending on the consistency and integrity of the tissue (amplitude 2–3 mm, speed
0.5–1.5 mm/s).
(VII) Once uniform 250 µm thick slices are obtained, gently scoop out of the bath using a sterile spatula or forceps.
(VIII) Place each slice in one well of a 48 well dish containing prewarmed modified WME media.
(IX) Each core and slice were assigned a numerical value so that the sequence and orientation of slices were tracked and
documented.
(X)
Once a 48 well plate was filled with slices it was placed at 37 degrees on a rocker (20 rocks/minute) for 1–4 hours for
washing.
Determination of viability, MTS assay
(I)
(II)
(III)
(IV)
(V)
(VI)
(VII)
(VIII)

Thaw 5 mL aliquots of CellTiter 96 Aqueous One Solution in the 37-degree water bath.
Place 400 µL of modified WME into each well of a 48 well dish.
Transfer slices to individual wells. Keeping track of slice identification number. Keep 3 wells without slices for blanks.
Add 80 µL of CellTiter 96 Aqueous One Solution to each well of the plate.
Incubate plate on rocker for 3 hours. (Note: media and slice will change purple).
Transfer 200 µL of each blank and each slice well to a 96 well assay plate.
Read plate at 490 nm, blanks are averaged and subtracted from the values of the slices.
At this point slices can be fixed or transferred back to initial Millicell insert for further culturing.

Preparation of tissue for histology
(I)
(II)
(III)

Tissue slices are fixed in 400 µL of 10% formalin in a 48 well dish at 4 ℃ for 24 hours.
Tissue slices were placed in one compartment each of a six compartment microsette biopsy cassette. Cassettes were
labeled with identification code of each slice in each compartment. Cassettes were placed in 70% ethanol.
Tissue was embedded in paraffin in the orientation placed in the cassette and 4 µm sections were cut and mounted on
slides.

Table S1 Characteristics of patients listed in Figure 3
Tumor type
Total cases, n
Age, mean ± SD
[range]

Primary liver tumors

All Participants

Metastatic liver tumors

HCC

ICC

HCC-ICC

Other

CRC

Other

7

6

2

5

25

8

53

55±13 [26–77] 55±17 [25–77] 57±16 [36–69] 45.5±13.6 [28–63] 36.7±2.3 [34–38] 55.9±10.4 [37–71] 51.9±14.2 [36–72]

Male, n [%]
MTS, mean ± SD

31 [57]

5 [71]

5 [83]

1 [50]

1 [20]

14 [56]

3 [38]

1.50±0.84

1.39±0.81

1.72±0.9

1.6±0.19

1.7±0.67

1.52±0.85

0.9±0.22

HCC, hepatocellular carcinoma; ICC, intra-hepatic cholangiocarcinoma; CRC, colorectal carcinoma; SD, standard deviation.

Table S2 Comparative predictive accuracy of multiple multivariate
models using leave-one-out cross-validation
Model # Model covariates

RMSEa

R2

Complete
cases (n=53)

0

Age
Male
Histologic cancer type
Metastatic disease
Maximum tumor size
Primary tumor size
Maximum focus size
% Necrosis

0.858

0.0366

39

1

Age
Histologic cancer type
Metastatic disease
Maximum tumor size
Primary tumor size
Maximum focus size
% Necrosis

0.864

0.0281

39

2*

Histologic cancer type
Metastatic disease
Maximum tumor size
Maximum focus size
% Necrosis

0.760

0.130

43

3

Metastatic disease
Maximum tumor size
Maximum focus size
% Necrosis
N Stage

0.770

0.100

39

4**

Metastatic disease
Maximum tumor size
Maximum focus size
% Necrosis

0.727

0.159

43

5

Metastatic disease
Maximum tumor size
% Necrosis
N Stage

0.828

0.0888

44

6

Metastatic disease
Maximum tumor size
% Necrosis

0.779

0.157

48

7

Histologic cancer type
Maximum tumor size
% Necrosis

0.79

0.142

48

8

Maximum tumor size
% Necrosis

0.784

0.137

48

9

% Necrosis

0.807

0.0816

48

a

RMSE, root-mean-square error. , Lower RMSE and higher
R2 indicate better predictive accuracy for this data. *, Original
model hypothesized a priori to be best predictive model. **,
Model with best predictive accuracy.

